Track EVMN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Evommune, Inc.
1891 Page Mill Road, Palo Alto, CA, United States, 94304
IPO
2025
Employees
48
Industry
Biotechnology
Sector
Healthcare
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20250+1
1
Analyst Ratings
No coverage data
No analyst ratings data available